Intended Audience:
This webcast is designed for all practitioners with the following specialties or subspecialties: Orthopedic and other surgeons, orthopedic anesthesiologists, and other healthcare providers who manage patients undergoing orthopedic procedures.

Registration:
Enrollment for this webcast is complimentary, and clinicians are invited to attend this CME-certified webcast and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:
Supported by an independent educational grant from Eisai Pharmaceuticals.

Accreditation Statement for Jointly-Sponsored Programs:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:
The University of Massachusetts Medical School designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

Javad Parvizi, MD, FRCS
Grant/Research Support: NIH, OREF, DOD, Aircast., GSK, Ortho McNeill, Pfizer, Smith and Nephew, Stryker
Consultat: Stryker
Speaker's Bureau: Endo

Peter B. Hanson, MD
Speaker's Bureau: Eisai, sanofi-aventis, Bristol-Myers Squibb
Russell Hull, MBBS, MSc
Grant/Research Support: sanofi-aventis, Bayer
Consultant: sanofi-aventis, Wyeth, GSK, Leo Pharmaceuticals, Pfizer, Bayer

Russell Hull, MBBS, MSc
Grant/Research Support: sanofi-aventis, Bayer
Consultant: sanofi-aventis, Wyeth, GSK, Leo Pharmaceuticals, Pfizer, Bayer

Eugene R Viscusi, MD
Research Support: Ortho-McNeil Pharmaceutical, Inc., Endo Pharmaceuticals, SkyePharma, Pfizer Inc, Xsira Pharmaceuticals, Baxter Pharmaceutical Products, Inc., and Progenics Pharmaceuticals, Inc. Consultant: Ortho-McNeil Pharmaceutical, Inc., Adolor Corporation, Endo and SkyePharma Speaker's Bureau: Endo

Paul F. Lachiewicz, MD
Consultant: Zimmer, Endo
Research Grant: Aircast

Program Faculty

Javad Parvizi, MD, FRCS
Associate Professor
Department of Orthopedics
Thomas Jefferson University
Rothman Institute
Philadelphia, PA

Peter B. Hanson, MD
Medical Director of Orthopedics
Chief of Staff
Grossmont Hospital
La Mesa, CA

Russell Hull, MBBS, MSc
Professor of Medicine
Director, Thrombosis Research Unit
University of Calgary
Calgary, Alberta
Canada

Eugene R Viscusi, MD
Director, Acute Pain Management
Associate Professor
Department of Anesthesiology
Thomas Jefferson University
Philadelphia, PA

Paul F. Lachiewicz, MD
Department of Orthopaedics
University of North Carolina School of Medicine
Chapel Hill, NC

Educational Objectives:

• Learn how to apply current guidelines issued by national professional organizations and colleges, such as the AAOS, ACCP, and ASA, mandating risk-directed prophylaxis against DVT in low-to-high risk patients undergoing orthopedic surgery.

• Learn how to risk stratify orthopedic surgery patients undergoing THA, TKA, fracture repair, and assess their likelihood for incurring DVT.

• Learn how to apply pharmacologic and/or intermittent compression devices as part of a multimodal prophylaxis strategy aimed at the incidence of DVT in the OS patient population.

• Learn how to select pharmacologic agents used for DVT prophylaxis based on an analysis of efficacy, safety, and pharmacoeconomic parameters.

• Learn to assess, diagnose, and manage special anesthesiological needs of OS patients at risk for DVT, with a focus on timing of prophylaxis, transitioning agents, and duration of prophylaxis based on the surgical procedure.

• Learn to risk stratify patients undergoing orthopedic surgery, and implement ACCP-mandated pharmacologic and non-pharmacologic measures aimed at DVT prophylaxis.

• Learn how to apply landmark clinical trials focusing on DVT prevention in OS patients.

• Learn how to evaluate, select among, and appropriately use the range of pharmacologic options available for DVT prophylaxis, including warfarin, unfractionated heparin, and LMWHs.